U.S., March 18 -- ClinicalTrials.gov registry received information related to the study (NCT06879236) titled 'Secondary and Tertiary Digital Prevention of Non-alcoholic and Dysmetabolic Liver Disease' on Sept. 26, 2024.
Brief Summary: The prevalence of Metabolic dysfunction-associated steatotic liver disease (MASLD) and its severe form, Metabolic dysfunction-associated steatohepatitis (MASH), is high and they are increasingly becoming major causes of cirrhosis, hepatocellular carcinoma (HCC), and the need for liver transplantation. Due to the lack of noticeable symptoms during the early stages, the detection of MASLD is often delayed until the disease has advanced.
Currently, the treatment options MASLD are limited to lifestyle interventi...